ADA: Invokana Obesity Data 'Astounds' Janssen
Executive Summary
Johnson & Johnson subsidiary, Janssen Pharmaceuticals Inc., believes it has a game-changing obesity treatment in its portfolio – with potential in both diabetic and non-diabetic patients – in the form of marketed type 2 diabetes drug, Invokana (canagliflozin).